Anavex Life Sciences Corp. (Nasdaq: AVXL) has announced that it has regained compliance with Nasdaq Listing Rule 5250(c)(1), which mandates that listed companies file all required periodic financial reports with the Securities and Exchange Commission (SEC).
The company confirmed the status on September 2, 2026, following a period of non-compliance that began in May 2026. On May 20, 2026, Anavex received a delinquency notification from the Nasdaq Listing Qualifications Department due to its inability to file its Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2026.
To address the issue, the company submitted a plan to Nasdaq on July 20, 2026. The plan was executed on August 28, 2026, when Anavex filed its outstanding quarterly reports with the SEC. Specifically, the company filed its Form 10-Q for the quarterly period ended March 31, 2026, and its Form 10-Q for the quarterly period ended June 30, 2026.
As a result of these filings, Anavex is now in compliance with all Nasdaq listing standards. The company’s common stock will continue to trade on the Nasdaq Global Select Market under the ticker symbol AVXL.
